Intracellular expression of an antibody fragment-neutralizing p21 Ras promotes tumor regression

Cancer Research

Volumn 58, Issue 6, 1998, Pages 1170-1176

  Cochet, Olivier ^a   Kenigsberg, Mireille ^b   Delumeau, Isabelle ^b   Virone Oddos, Angela ^b   Multon, Marie Christine ^b   Fridman, Wolf Herman ^a   Schweighoffer, Fabien ^b   Teillaud, Jean Luc ^a   Tocqué, Bruno ^b  

^a INSTITUT CURIE   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN P21; RAS PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN 3T3; COLON CARCINOMA; CONTROLLED STUDY; FIBROBLAST; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; XENOPUS LAEVIS;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; GENES, P53; GENES, RAS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; MICE; MICE, NUDE; MICROINJECTIONS; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; XENOPUS LAEVIS;

EID: 0032521206     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
2. Mills, N. E., Fishman, C. L., Rom, W. N., Dubin, N., and Jacobson, D. R. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res., 55-1444-1447, 1995.
3. Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S. S., Vanderschueren, R. G. J. R. A., Van Zandwijk, N., Mooi, W. J., Bos, J. L., and Rodenhuis, S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med., 323: 561-565, 1990.
4. Sklar, M. D. The ras oncogenes increase the intrinsic resistance of NIH3T3 cells to ionizing radiations. Science (Washington DC), 239: 645-647, 1988.
5. Sklar, M. D. Increased resistance to cis-diamminedichloroplatinum(II) in NIH3T3 cells transformed by ras oncogenes. Cancer Res., 48: 793-797, 1988.
6. Georges, R. N., Mukhopadhyay, T., Zhang, Y., Yen, N., and Roth, J. A. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res., 53: 1743-1746, 1993.
7. Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (Washington DC), 260: 85-88, 1993.
8. Gibbs, J. B. Pharmacological probes of Ras function. Semin. Cancer Biol., 3: 383-390, 1992.
9. Galang, C. K., Garcia-Ramirez, J. J., Solski, P. A., Westwick, J. K., Der, C. J., Neznanov, N. N., Oshima, R. G., and Hauser, C. A. Oncogenic Neu/ErbB-2 increases ets, AP-1 and NF-κB-dependent gene expression, and inhibiting its activation blocks Neu-mediated cellular transformation. J. Biol. Chem., 271: 7992-7998, 1996.
10. Smith, M. R., DeGudicibus, S. J., and Stacey, D. W. Requirement for c-ras proteins during viral oncogene transformation. Nature (Lond.), 320: 540-542, 1986.
11. Prendergast, G. C., Davide, J. P., deSolms, S. J., Giuliani, E. A., Graham, S. L., Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol., 14: 4193-4202, 1994.
12. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., deSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G. D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice Nat Med., 1: 792-797, 1995.
13. Mhashilkar, A. M., Bagley, J., Chen, S. Y., Szilvay, A. M., Helland, D. G., and Marasco, W. A. Inhibition of HIV-1 tat-mediated LTR transactivation and HIV-1 infection by anti-tat single chain intrabodies. EMBO J., 14: 1542-1551, 1995.
14. Duan, L., Bagasra, O., Laughlin, M. A., Aokes, J. W., and Pomerantz, R. J. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-rev single-chain antibody. Proc. Natl. Acad. Sci. USA, 91: 5075-5079, 1994.
15. Furth, M. E., Davis, L. J., Fleurdelys, B. E., and Scolnick, M. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J. Virol., 43: 294-304, 1982.
16. ras protein. FEBS Lett., 274: 193-198, 1990.
17. Werge, T. M., Baldari, C. T., and Telford, J. L. Intracellular single chain Fv antibody inhibits ras activity in T-cell antigen receptor stimulated Jurkat cells. FEBS Lett., 351: 393-396, 1994.
18. Biocca, S., Pierandrei-Amaldi, P., Campioni, N., and Cattaneo, A. Intracellular immunization with cytosolic recombinant antibodies. Bio/Technology, 12: 396-399, 1994.
19. ras single-chain Fv fragments inhibits meiotic maturation of Xenopus oocytes. Biochem. Biophys. Res. Commun., 197: 422-427, 1993.
20. Deshane, J., Loechel, F., Conry, R. M., Siegal, G. P., King, C. R., and Curiel, D. T. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther., 1: 332-337, 1994.
21. Graus-Porta, D., Beerli, R. R., and Hynes, N. E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol., 15: 1182-1191, 1995.
22. Kung, H. F., Smith, M. R., Bekesi, E., Manne, V., and Stacey, D. W. Reversal of transformed phenotype by monoclonal antibodies against Ha-ras p21 proteins. Exp Cell Res., 162: 363-371, 1986.
23. Stacey, D. W., Watson, T., Kung, H. F., and Curran, T. Microinjection of transforming ras protein induces c-fos expression. Mol. Cell. Biol., 7: 523-527, 1987.
24. Deshpande, A. K., and Kung, H. F. Insulin induction of Xenopus laevis oocyte maturation is inhibited by monoclonal antibody against p21 ras proteins. Mol. Cell. Biol., 7: 1285-1288, 1987.
25. Fox, P. L., Sa, G., Dobrowolski, S. F., and Stacey, D. W. The regulation of endothelial cell motility by p21 ras. Oncogene, 9: 3519-3526, 1994.
26. Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., and Winter, G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature (Lond.), 341: 544-546, 1989.
27. Tocqué, B., Janicot, M., and Kenigsberg, M. Oocyte microinjection assay for evaluation of Ras-induced signaling pathways. Methods Enzymol., 255: 426-435, 1995.
28. Orlandi, R., Güssow, D. H., Jones, P. T., and Winter, G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 86: 3833-3837, 1989.
29. Clackson, T., Hoogenboom, H. R., Griffiths, A. D., and Winter, G. Making antibody fragments using phage display libraries. Nature (Lond.), 352: 624-628, 1991.
30. Stratford-Perricaudet, L. D., Makeh, I., Perricaudet, M., and Briand, P. Widespread long-term gene transfer to mouse skeletal muscle and heart. J. Clin. Invest., 90: 626-630, 1992.
31. Graham, F. L., and Prevec, L. Manipulation of adenovirus vectors. In: E. J. Murray (ed.), Gene Transfer and Expression Protocols: Methods in Molecular Biology, Vol. 7, pp. 109-128. Clifton, NJ: Humana Press Inc., 1991.
32. Fath, I., Schweighoffer, F., Rey, I., Multon, M. C., Boiziau, J., Duchesne, M., and Tocqué, B. Cloning of a Grb2 isoform with apoptotic properties. Science (Washington DC), 264: 971-974, 1994.
33. Mulcahy, L. S., Smith, M. R., and Stacey, D. W. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH3T3 cells. Nature (Lond.), 313: 241-243, 1985.
34. Roden, R. B. S., Shachar-Hill, Y., Cosulich, S. C., Hesketh, T. R., and Metcalfe, J. C. A common requirement for p21c-ras function in the mitogenic signaling pathways of Swiss 3T3 fibroblasts. Cell Growth Differ., 4: 957-964, 1993.
35. Wasylyk, C., Flores, P., Gutman, A., and Wasylyk, B. PEA3 is a nuclear target for transcription activation by non-nuclear oncogenes. EMBO J., 8: 3371-3378, 1989.
36. Harris, M. P., Sutjipto, S., Wills, K. N., Hancock, W., Cornell, D., Johnson, D. E., Gregory, R. J., Shepard, H. M., and Maneval, D. C. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther., 3: 121-130, 1996.
37. Lazaris-Karatzas, A., Smith, M. R., Frederickson, R. M., Jaramillo, M. L., Liu, Y., Kung, H. F., and Sonenberg, N. Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev., 6: 1631-1642, 1992.
38. Rinker-Schaeffer, C. W., Austin, V., Zimmer, S., and Rhoads, R. E. ras transformation of cloned rat embryo fibroblasts results in increased rates of protein synthesis and phosphorylation of eukaryotic initiation factor 4E. J. Biol. Chem., 267: 10659-10664, 1992.
39. Kinoshita, T., Yokota, T., Arai, K. I., and Miyajima, A. Regulation of bcl-2 expression by oncogenic ras protein in hematopoietic cells. Oncogene, 10: 2207-2212, 1995.
40. Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evan, G. Suppression of c-myc-induced apoptosis by ras signalling through PI(3)K and PKB. Nature (Lond.), 385: 544-548, 1997.
41. Cleveland, J. L., Troppmair, J., Packham, G., Askew, D. S., Lloyd, P., Gonzalez-Garcia, M., Nuñez, G., Ihle, J. N., and Rapp, U. R. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene, 9: 2217-2226, 1994.
42. Sakai, N., Ogiso, Y., Fujita, H., Watari, H., Koike, T., and Kuzumaki, N. Induction of apoptosis by a dominant negative H-RAS mutant in K562 cells. Exp. Cell Res., 215: 131-136, 1994.
43. Chin, K. V., Ueda, K., Pastan, I., and Gottesman, M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (Washington DC), 255: 459-462, 1992.
44. Ostad, M., Shu, W. P., Kong, L., and Liu, B. C. S. Ha-ras oncogene expression abrogates a pH-dependent endonuclease activity of apoptosis in normal rat kidney cells. Cancer Lett., 98: 175-182, 1996.
45. Fernandes, R. S., McGowan, A. J., and Cotter, T. G. Mutant H-ras overexpression inhibits drug- and U.V.-induced apoptosis. Anticancer Res., 16: 1691-1706, 1996.
46. Bernhard, E. J., Kao, G., Cox, A. D., Sebti, S. M., Hamilton, A. D., Muschel, R. J., and McKenna, W. G. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-Ras-transformed rat embryo fibroblasts. Cancer Res., 56: 1727-1730, 1996.
47. Arends, M. J., McGregor, A. H., Toft, N. J., Brown, E. J. H., and Wyllie, A. H. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br. J. Cancer, 68: 1127-1133, 1993.
48. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95(APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
49. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
50. Bates, R. C., Buret, A., van Helden, D. F., Horton, M. A., and Burns, G. F. Apotosis induced by inhibition of intercellular contact. J. Cell. Biol., 125: 403-415, 1994.
51. Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., and Marmé, D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH3T3 cells. J. Biol. Chem., 270: 25915-25919, 1995.
52. Nooter, K., Boersma, A. W. M., Oostrum, R. G., Jochemsen, A. G., and Stoter, G. Constitutive expression of the c-Ha-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br. J. Cancer 71: 556-561, 1995.